Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.
about
Medical and surgical treatment for ocular myastheniaMedical and surgical treatment for ocular myastheniaMedical and surgical treatment for ocular myastheniaClinical predictors for the prognosis of myasthenia gravisQuality of life in purely ocular myasthenia in Japan.Treatment of myasthenia gravis.Ocular myasthenia gravis: a review.Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis.Current and emerging therapies for the treatment of myasthenia gravis.Myasthenia gravis: a clinical-immunological update.Current management options in myasthenia gravis.Safety of prednisone for ocular myasthenia gravis.EFNS/ENS Guidelines for the treatment of ocular myasthenia.Glucocorticoids in myasthenia gravis - if, when, how, and how much?Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.Azathioprine in the management of autoimmune uveitis.Ocular presentation of myasthenia gravis: A natural history cohort.Low conversion rate of ocular to generalized myasthenia gravis in Singapore.Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.Ocular myasthenia gravis: controversies and updates.Editors’ Introduction
P2860
Q24202289-F49FCAE8-7106-4F80-8C7C-8379939F7F24Q24245255-1C424676-F934-4EFE-BEE1-450B6E0FE36FQ24246392-38BCF4CD-69D0-495B-AAA2-B38C8FC88F34Q33577194-D2D584B4-F9F1-4F33-9E2B-7A3B56D5E6D0Q33869796-2F5E9CA8-2B35-45C4-B108-57A90A818CE0Q34142187-DA0E4568-8AE5-45B7-A07B-F6D281F09771Q34450858-90460A0E-C4EA-4F64-9EA4-33AF94639986Q34575021-B6046B50-06B0-492D-A76A-A54F6908BBF5Q34879129-CE036293-7EFD-495A-98D5-1BFF6D5A0246Q36783864-B2A7184D-DF7D-4432-A3B4-16B9928B5EE3Q36839974-E85DE196-AF32-4D1C-900D-DEAD0FCBBC61Q37063766-8DA60BB4-5FF5-4BC6-8E39-72C33DBC60EBQ38182650-DCEBA3A5-A33B-4716-8EFB-A3FC982548EFQ38234725-55BB6E48-F419-4D36-BCFB-CD906A7401ADQ43240738-1B697F60-F2EF-4511-8468-6119F0D477D9Q44046461-7EB8E34B-E034-4150-A7FD-CFCE0A6B2684Q46419314-815D076E-FFD0-42D7-9AE1-4BAA3A70DD36Q48020624-96AC781F-71D0-45BA-8552-A2676A805415Q49582626-ED6CC55F-2304-413F-87C7-347D3DF48C12Q50954321-83DFA2A3-000E-474A-9939-89C070FC9A11Q53118752-F32000FC-95D7-4E91-A502-662E6ADF6C28Q54394549-3305CCBD-6A14-4032-A34F-D513E0D8FF16Q57642468-BCD29122-2AE1-4953-B69E-295E5414051D
P2860
Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@ast
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@en
type
label
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@ast
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@en
prefLabel
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@ast
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@en
P2093
P1476
Immunotherapy of ocular myasth ...... generalized myasthenia gravis.
@en
P2093
Edward Byrne
Justin O'Day
Katrina Reardon
Mark Paine
P304
P356
10.1097/00041327-200312000-00002
P577
2003-12-01T00:00:00Z